Greg recently graduated from Cornell University and joined the group in September 2017, as a research scientist. Greg will be working on the synthesis of novel molecules as potential treatments for a number of neurodegenerative diseases. In the future, Greg also plans to pursue a career in medicine.
Dawid originally joined the group in January 2017, as a coop student from Northeastern University. Dawid worked on the synthesis of analogs in our SMA series that increases transcription of the survival motor neuron protein for the treatment of Spinal Muscular Atrophy. Dawid is also developing water soluble pro-drugs of a poorly soluble drug that we are re-purposing for AD. Dawid is currently doing undergraduate research in the lab. In the future, he plans to attend medical school.
Dr. Kevin Hodgetts
Director of The Laboratory for Drug Discovery in Neurodegeneration
65 Landsdowne Street
Cambridge, Massachusetts 02139
Kevin has a broad background in organic and medicinal chemistry, with experience in both industrial and academic drug discovery. Kevin spent over 15 years of experience working on treatments for diseases of the central nervous system. Compounds from two projects that he was involved in have entered clinical trials. Kevin joined the LDDN in September 2012, to work with the academic community to design new and innovative strategies for drug discovery for neurodegenerative diseases. Kevin is Assistant Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School. He also co-founded Klogene Therapeutics with Professor Carmela Abraham.
Lin Lin originally joined the group in January 2015, as a coop student from Northeastern University. Lin developed the SAR on the SOD1 and CMT projects. After graduating from Northeastern, Lin is now back at the LDDN and making key contributions to the EAAT2 and HIF projects. In the future, Lin plans to attend medical school.